ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease

Author:

Apostolova Liana G.,Hwang Kristy S.,Kohannim Omid,Avila David,Elashoff David,Jack Clifford R.,Shaw Leslie,Trojanowski John Q.,Weiner Michael W.,Thompson Paul M.

Funder

Alzheimer's Disease Neuroimaging Initiative (ADNI)

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

Abbott

Alzheimer's Association

Alzheimer's Drug Discovery Foundation

Amorfix Life Sciences Ltd.

AstraZeneca

Bayer HealthCare

BioClinica, Inc.

Biogen Idec Inc.

Bristol-Myers Squibb Company

Eisai Inc.

Elan Pharmaceuticals Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Genentech, Inc.

GE Healthcare

Innogenetics, N.V.

IXICO Ltd.

Janssen Alzheimer Immunotherapy Research & Development, LLC.

Johnson & Johnson Pharmaceutical Research & Development LLC.

Medpace, Inc.

Merck & Co., Inc.

Meso Scale Diagnostics, LLC.

Novartis Pharmaceuticals Corporation

Pfizer Inc.

Servier

Synarc Inc.

Takeda Pharmaceutical Company

Canadian Institutes of Health Research

NIH

Easton Consortium for Alzheimer's Drug Discovery and Biomarker Development

NIMH

NIA

UCLA Dissertation Year Fellowship

UCLA Medical Scientist Training Program

National Institutes of Health

Easton Consortium for Alzheimer's Drug Development and Biomarker Discovery

Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation

MJFox Foundation for Parkinson's Research

NeuroVigil, Inc.

CHRU-Hopital Roger Salengro

Siemens

Geneva University Hospitals

Lilly

University of California

San Diego — ADNI

Paris University

Institut Catala de Neurociencies Aplicades

University of New Mexico School of Medicine

Ipsen

CTAD (Clinical Trials on Alzheimer's Disease)

Pfizer

ADPD meeting

Paul Sabatier University

Novartis

Tohoku University

Fundacio ACE and Travel eDreams, Inc.

Publisher

Elsevier BV

Subject

Cognitive Neuroscience,Neurology (clinical),Neurology,Radiology, Nuclear Medicine and imaging

Reference63 articles.

1. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice;Andreasen;Arch. Neurol.,2001

2. Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment;Apostolova;Neuropsychologia,2008

3. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps;Apostolova;Arch. Neurol.,2006

4. Subregional hippocampal atrophy predicts future decline to Alzheimer's dementia in cognitively normal subjects;Apostolova;Neurobiol. Aging,2014

5. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI;Apostolova;Hum. Brain Mapp.,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3